Reduced major organ morbidity or mortality (MOMM)
A randomised, controlled clinical study demonstrated that monitoring cerebral rSO2 in coronary artery bypass patients avoids profound cerebral desaturation and is associated with significantly fewer incidences of major organ dysfunction.1
- Only 3% of the INVOS™ system group experienced MOMM compared to 11% in the control group and compared to 13.4% from the Society of Thoracic Surgeons database.
Reduced length of ICU stay1
Also clinically demonstrated, ICU length of stay for the INVOS™ system group was significantly shorter.1
- Mean 0.62 day reduction in length of stay, p<0.029.
Reduced incidence of stroke and need for prolonged ventilation
The INVOS™ system use on cardiac surgery patients reduced permanent stroke and reduced total time needed for mechanical ventilation.2
- Incidence of permanent stroke <1% in the INVOS system group compared to 2% in the control group, p<0.0442
- The study group had greater comorbidities than those in the control group
- Rated using New York Heart Association (NYHA) classifications
- Median ventilator time of four hours vs. five hours in the control group, p<0.0016. A significantly greater proportion of the patients in the control group required prolonged ventilation, 10.6% vs. 6.8%, p<0.0014.2